Bavarian Nordic Initiates Phase I/II Study of HIV Vaccine
Posted on: Tuesday, 27 May 2008, 09:01 CDT
Bavarian Nordic has initiated Phase I/II clinical study with its HIV vaccine candidate MVA-BN HIV multiantigen.
A Phase I/II safety and immunogenicity study in 15 HIV-infected patients (CD4 counts > 350 ul/ml) has begun enrolment in the US. The first safety data are expected by the end of 2008, while the immunogenicity data will be available during the first half of 2009.
The MVA-BN HIV multiantigen vaccine encodes eight genes from HIV, including Nef and is said to represent a more advanced vaccine candidate compared to Bavarian Nordic's previous MVA-based HIV vaccine candidates, MVA HIV nef and MVA-BN HIV polytope.
Anders Hedegaard, president & CEO of Bavarian Nordic, said: "Our expertise in HIV vaccine development has expedited the development of the multiantigen vaccine and it is exciting that we now again are in clinical development with an HIV vaccine candidate."
Source: Datamonitor
Related Articles
- VGX Pharmaceuticals Awarded $23.5 Million NIH Contract to Develop DNA-Based Preventive HIV Vaccine Delivered Via Electroporation
- Orchestra Therapeutics Discontinues Its HIV Vaccine Development Program
- Crucell Secures $16.2 Million NIH Contract for HIV Vaccine Design and Development
- Gates Foundation Funds Major New Collaboration to Accelerate HIV Vaccine Development
- Willingness to Participate in HIV Vaccine Research in a Peri-Urban South African Community
- Targeted Genetics Named As Subcontractor to NIAID Contract to Expand AAV-Based HIV Vaccine Program; NIAID Funding to Total Approximately $22 Million
- IAVI Begins First Phase II Preventive HIV Vaccine Trial in South Africa to Test Targeted Genetics' HIV Vaccine Candidate
- Gaithersburg-Based GenVec's HIV Vaccine Candidate Continues to Generate Funding
- Study Shows Barriers to HIV Vaccine Acceptance
 |
 |
User Comments (0)
RSS Feeds